RPRX
Royalty Pharma plc
Stock
$57.16−0.47 (−0.82%)Close Oct 2, 2026
Income statement
| Line | Last 12 months | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.5B | $2.4B | $2.3B | $2.4B | $2.2B | $2.3B | $2.1B | $1.8B | $1.8B |
| R&D | $239M | $452M | $2.0M | $52M | $177M | $200M | $26M | $83M | $393M |
| Operating income | $1.5B | $1.6B | $1.3B | $1.5B | $307M | $1.4B | $1.6B | $2.6B | $1.4B |
| Non-operating income | −$162M | −$235M | $38M | $208M | −$77M | −$190M | $107M | −$162M | $153M |
| Pretax income | $1.3B | $1.3B | $1.3B | $1.7B | $230M | $1.2B | $1.7B | $2.5B | $1.5B |
| Taxes | $535M | $553M | $472M | $565M | $187M | $621M | $727M | $113M | $140M |
| Net income | $815M | $771M | $859M | $1.1B | $43M | $620M | $975M | $2.3B | $1.4B |
| Diluted EPS | $1.88 | $1.78 | $1.91 | $2.53 | $0.10 | $1.49 | $1.32 | — | — |
| Diluted shares | — | 564.5M | 594.1M | 602.9M | 438.0M | 414.8M | 375.5M | — | — |
| Revenue growth | — | +5.1% | −3.9% | +5.2% | −2.3% | +7.9% | +17.0% | +1.1% | — |
| Operating margin | 59.6% | 65.6% | 57.1% | 63.4% | 13.7% | 62.5% | 75.2% | 144.6% | 76.0% |
| Net margin | 32.1% | 32.4% | 37.9% | 48.2% | 1.9% | 27.1% | 45.9% | 129.4% | 76.8% |